My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 272

    1.

    Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.

    Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR.

    Diabetes. 2003 Mar;52(3):667-74.PMID: 12606507 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects.

    Ciaraldi TP, Kong AP, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowski R, Reitz R, Caulfield M, Mudaliar S, Henry RR.

    Diabetes. 2002 Jan;51(1):30-6.PMID: 11756319 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.

    Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB.

    Diabetes. 2002 Feb;51(2):443-8.PMID: 11812753 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.

    Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM.

    Diabetes. 2002 Oct;51(10):2968-74.PMID: 12351435 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

    Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947. PMID: 11874944 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.

    Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR.

    Metabolism. 2003 May;52(5):540-6.PMID: 12759881 [PubMed - indexed for MEDLINE]Related articles

    7.

    The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus.

    Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS.

    Metabolism. 2005 Mar;54(3):314-20.PMID: 15736108 [PubMed - indexed for MEDLINE]Related articles

    8.

    A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.

    Diabetes. 1999 Dec;48(12):2414-21.PMID: 10580431 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effect of troglitazone on body fat distribution in type 2 diabetic patients.

    Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y.

    Diabetes Care. 1999 Jun;22(6):908-12.PMID: 10372240 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.

    Frias JP, Yu JG, Kruszynska YT, Olefsky JM.

    Diabetes Care. 2000 Jan;23(1):64-9.PMID: 10857970 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.

    Hershon KS, Hershon PM.

    Endocr Pract. 2000 Jan-Feb;6(1):20-5.PMID: 11419922 [PubMed - indexed for MEDLINE]Related articles

    12.

    Efficacy of troglitazone on body fat distribution in type 2 diabetes.

    Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K.

    Diabetes Care. 2000 Aug;23(8):1067-71.PMID: 10937499 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

    Plosker GL, Faulds D.

    Drugs. 1999 Mar;57(3):409-38. Review.PMID: 10193691 [PubMed - indexed for MEDLINE]Related articles

    14.

    Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.

    Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI.

    Metabolism. 2004 Nov;53(11):1454-61.PMID: 15536601 [PubMed - indexed for MEDLINE]Related articles

    15.

    Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

    Strowig SM, Avilés-Santa ML, Raskin P.

    Diabetes Care. 2002 Oct;25(10):1691-8.PMID: 12351463 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice.

    Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka N, Shimotomai T, Morii T, Narita T, Kakei M, Ito S.

    Endocr J. 2005 Aug;52(4):427-33.PMID: 16127210 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.

    N Engl J Med. 1998 Mar 26;338(13):867-72.PMID: 9516221 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans.

    Phillips SA, Kung J, Ciaraldi TP, Choe C, Christiansen L, Mudaliar S, Henry RR.

    Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E767-73. Epub 2009 Jul 21.PMID: 19622782 [PubMed - indexed for MEDLINE]Related articles

    19.

    Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.

    Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T.

    Metabolism. 2002 Mar;51(3):314-7.PMID: 11887166 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.

    Kruszynska YT, Yu JG, Olefsky JM, Sobel BE.

    Diabetes. 2000 Apr;49(4):633-9.PMID: 10871202 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity